3rd World Congress of Cutaneous Lymphomas is Organized by Columbia University College of Physicians and Surgeons and would be held during Oct 26 - 28, 2016 at Alfred Lernerm, New york city, New York, United States of America.
The target audience for this medical event basically for Dermatologists. This CME Conference has been approved with a maximum of 21.5 AMA PRA Category 1 Credits.
The aim of the conference is to review the current state and to pave the road to the new developments in the basic, translational and clinical research in cutaneous lymphomas and other lymphoproliferative disorders. The technological advances have enabled numerous recent discoveries in genomic and mutational landscapes in cutaneous lymphomas, which have significant implications for development of true personalized approaches to therapy. In this context, the congress will specifically focus on the basic, translational and clinical aspects of the exciting new developments, including biomarkers and molecular pathways analysis, targeted therapies, including novel antibodies specific for cell surface molecules that direct toxins, immune therapies, kinase inhibitors, and combination therapies among others.
The congress will also feature number of educational and didactic lectures of interest to the practicing physicians and trainees across several disciplines, highlighting the state-of-the-art in current therapeutic approaches to cutaneous lymphomas, including the place for stem cell transplantation for aggressive cutaneous lymphomas. The Congress will cover difficult to treat and rare skin lymphomas from around the world. The congress will provide ample opportunities for discussions across disciplines among dermatologists, dermatopathologists, oncologists, radiation oncologists, pharmacologists, basic and translational scientists, patient advocates and industry partners. The Congress continues the tradition of being a forum for exchange of information and ideas in the cutaneous lymphoma and related communities.
Copyrights © 2026 eMedEvents Corporation, All Rights Reserved